623 related articles for article (PubMed ID: 16243088)
1. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
[TBL] [Abstract][Full Text] [Related]
6. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
7. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
8. Alternatives to amphotericin B for Candida rugosa infection.
Hernandez S; Gonzalez GM; McCarthy DI; Colombo AL; Najvar LK; Bocanegera R; Graybill JR
J Antimicrob Chemother; 2004 Aug; 54(2):477-80. PubMed ID: 15215225
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
12. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
[TBL] [Abstract][Full Text] [Related]
13. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
14. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Manfredi R; Sabbatani S
Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
16. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.
Phillips P; Shafran S; Garber G; Rotstein C; Smaill F; Fong I; Salit I; Miller M; Williams K; Conly JM; Singer J; Ioannou S
Eur J Clin Microbiol Infect Dis; 1997 May; 16(5):337-45. PubMed ID: 9228472
[TBL] [Abstract][Full Text] [Related]
18. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
